Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

responsive web design (RWD)

- PMLiVE

A Stellar Start to 2021 for Lucid Group

It’s been a stellar start to 2021 for Lucid Group, which has welcomed 38 new starters into the company since the beginning of the year. These include 15 Client Services...

Lucid Group Communications Limited

- PMLiVE

Sanofi and Translate Bio launch phase 1/2 trial of mRNA-based COVID-19 vaccine

Vaccine candidate induced high antibody levels in preclinical studies

- PMLiVE

Lilly to expand donanemab study in a bid for approval in Alzheimer’s disease

Lilly revealed expanded findings from phase 2 TRAILBLAZER-ALZ study this week

- PMLiVE

AstraZeneca to supply US government with 500,000 additional doses of its COVID-19 antibody

AZD7442 is a long-acting antibody combination that could help to prevent and treat COVID-19

- PMLiVE

Roche buys GenMark for $1.8bn to bolster diagnostics portfolio

Swiss pharma company will gain respiratory pathogen panels to strengthen its COVID-19 testing capabilities

- PMLiVE

Is communication killing the COVID-19 vaccine’s chance at success?

Against the challenging backdrop of of misinformation, communications specialists are working to educate the public, change the minds of millions and fight to return to some sense of normality in...

Page & Page Health

- PMLiVE

New thinking, bold action: building a better future for people living with severe diseases

How UCB Neurology’s deep understanding of people living with neurological conditions is transforming the patient journey

Day in a #LucidLife – Meet Philippa

Ever wondered what a #LucidLife looks like?Philippa McClure, Senior Account Director, takes us through her day. We have a number of roles in client services, just like Philippa's.So, if you like what...

Lucid Group Communications Limited

- PMLiVE

Sanofi, Regeneron’s Libtayo shows marked reduction in risk of death in cervical cancer patients

Phase 3 trial showed drug reduced the risk of death by 31% compared to chemotherapy

- PMLiVE

WHO backs emergency use of J&J’s one-dose COVID-19 vaccine

Vaccine is already approved for emergency use by the European Commission and the FDA

- PMLiVE

Safety review shows ‘no evidence’ that AZ’s vaccine causes increased risk of blood clots

AZ's vaccine continues to be backed by the EMA and the EMA’s Pharmacovigilance Risk Assessment Committee

- PMLiVE

bluebird bio reveals long-term data for Lenti-D gene therapy in CALD

At 24 months of follow-up, 90% of patients were free of major functional disabilities

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links